RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I never said Lilly demonstrated 'superior capability.' They liked thinking they were superior, but as Gfp points out here, it turned out their platform had all the superiority of a certain unsinkable ocean liner in 1912. Their results in an animal model of Parkinson's were very impressive, but their compounds historically have not been viable in humans due to toxicity problems. There has never been a head to head (rodentwise, as it were) to 'compare' high-impacts. I don't know if Les Street has really solved the high-impact puzzle, but there's no evidence as of yet that Lilly has either. This is all yet-to-be-determined. And Cortex's immediate future does not rest on how the high impacts fare.

NeuroInvestment